US20090068150A1 - Lactic acid bacteria culture of mung bean and the preparation method of the same, and the cosmetic composition comprising the same - Google Patents

Lactic acid bacteria culture of mung bean and the preparation method of the same, and the cosmetic composition comprising the same Download PDF

Info

Publication number
US20090068150A1
US20090068150A1 US11/994,866 US99486606A US2009068150A1 US 20090068150 A1 US20090068150 A1 US 20090068150A1 US 99486606 A US99486606 A US 99486606A US 2009068150 A1 US2009068150 A1 US 2009068150A1
Authority
US
United States
Prior art keywords
mung bean
lactic acid
acid bacteria
culture
gaba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/994,866
Other languages
English (en)
Inventor
Chang-Seo Park
Sang-June Nam
Wang-Keun Choi
Yu-Ryang Pyun
Hyung-Yong Cho
Seok-Cheol Cho
Moo-Chang Kook
Chang-woo Lee
So-Young Chung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOVAN Co Ltd
Doosan Corp
Original Assignee
BIOVAN Co Ltd
Doosan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIOVAN Co Ltd, Doosan Corp filed Critical BIOVAN Co Ltd
Assigned to BIOVAN CO., LTD., DOOSAN CORPORATION reassignment BIOVAN CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHO, HUNG-YONG, CHO, SEOK-CHEOL, CHOI, WANG-KEUN, CHUNG, SO-YOUNG, KOOK, MOO-CHANG, LEE, CHANG-WOO, NAM, SANG-JUNE, PARK, CHANG-SEO, PYUN, YU-RYANG
Publication of US20090068150A1 publication Critical patent/US20090068150A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine

Definitions

  • the invention relates to a lactic acid bacteria culture obtained by culturing lactic acid bacteria in a culture medium comprising the mung bean extract and GABA, a method of preparing the culture, a cosmetic composition containing the same and a method of preparing the cosmetic composition.
  • GABA ⁇ -Aminobutyric acid
  • GABA is non-protein amino acid and is well known as a main inhibitory neurotransmitter of a central nervous system of an animal.
  • the GABA is known to participate in many physiological mechanisms to activate the blood stream of a brain and to increase the air supply, thereby promoting a metabolic function of brain cells.
  • the GABA participates in regulations of secretion of prolactin and growth hormone and has effect of decreasing the blood pressure and alleviating pains. Accordingly, the GABA arouses pharmacological interests.
  • the GABA can be used as functional food material and raw material of cosmetics.
  • PPAR peroxisome proliferators activated receptors
  • the PPAR is a factor of regulating an energy homeostasis, and in particular, participates in regulations of permeability of skin barrier and regulations of skin state such as suppression of multiplication of epidermal layer and induction of differentiation of epidermal layer, through various mechanisms, Owing to the features, the PPAR serves as a core regulator of various skin diseases such as psoriasis due to overgrowth of the epidermal layer, injury cure and acne as well as skin diseases related to inflammation.
  • PPAR phosphatidylserine
  • glucocorticoid Up to date, although materials such as glucocorticoid have been used as anti-inflammatory agent, they exhibit chronic side effects when they are continuously administrated or treated, so that an immunological reaction is decreased and thus there occurs limitations in the treatment. Thereby, it has been considered that the agonist of PPAR ⁇ is a local and effective treatment method, as compared to the glucocorticoid.
  • interleukin-6 which is cytokine
  • TNF- ⁇ which is peculiarly reacted with external antigens
  • the decreased interleukin-6 causes inflammatory reactions.
  • the decrease of expressions of the interleukin-6 is an index of suppressing the anti-inflammatory and hyperimmune reactions.
  • the mung bean Phaseolus aureus, Phaseolus radiatus
  • the mung bean exhibits skin cosmetic effects.
  • mung bean protein and mung bean flavonoid are effective in the cleansing and vitexin and isovitexin, which are physiological activating ingredients, have an effect of preventing skin senescence due to its excellent antioxidant effect.
  • the inventors conducted various tests for constituting a culture medium so as to develop a method capable of producing the GABA in a high concentration. As a result, the inventors confirmed that when lactic acid bacteria are cultured using mung bean as a main raw material of the culture medium, it can be obtained a culture containing the GABA as well as excellent ingredients originated from the mung bean, in high amounts.
  • the culture promotes collagen synthesis of the skin comprises a material acting as a ligand of PPAR ⁇ of a tissue cell in the skin, thereby alleviating an inflammatory reaction of the skin due to external stimulus and decreasing expression of interleukin-6 relating to anti-inflammatory and hyperimmune reactions.
  • An object of the invention is to provide a lactic acid bacteria culture of mung bean containing mung bean extract and GABA and a method of preparing the same.
  • Another object of the invention is to provide a cosmetic composition containing the lactic acid bacteria culture of mung bean containing the mung bean extract and GABA, as an effective ingredient, and a method of preparing the cosmetic composition.
  • Still another object of the invention is to provide a cosmetic composition for promoting collagen biosynthesis, preventing or improving skin senescence, anti-inflammatory and preventing or improving skin injury.
  • a lactic acid bacteria culture of mung bean obtained by culturing lactic acid bacteria in a culture medium containing the mung bean, the composition containing mung bean extract and GABA ( ⁇ -Aminobutyric acid).
  • the lactic acid bacteria culture of mung bean is obtained by seeding and culturing the lactic acid bacteria in a culture medium including the mung bean extract.
  • the lactic acid bacteria culture of mung bean is obtained by seeding and culturing the lactic acid bacteria in a culture medium including the mung bean extract and monosodium glutamate (MSG).
  • a culture medium including the mung bean extract and monosodium glutamate (MSG).
  • the mung bean extract is extracted with water.
  • the lactic acid bacteria are lactic acid bacteria capable of expressing glutamate dicarboxylase to convert the MSG into the GABA, preferably Lactobacillus sakei or Lactobacillus brevis.
  • a method of preparing a lactic acid bacteria culture of mung bean obtained by culturing lactic acid bacteria in a culture medium containing the mung bean comprising steps of: (a) preparing mung bean extract; (b) preparing a culture medium including the mung bean extract obtained in the step (a) and monosodium glutamate (MSG); (c) seeding lactic acid bacteria in the culture medium prepared in the step (b), the bacteria being capable of converting the MSG into GABA ( ⁇ -Aminobutyric acid) by glutamate dicarboxylase; and (d) culturing the lactic acid bacteria seeded in the step (c) to prepare a lactic acid culture of mung bean containing the mung bean extract and the GABA.
  • an addition amount of the MSG in the step (b) is 1 to 30 wt % for a total weight of the mung bean extract.
  • a method of preparing a cosmetic composition containing a lactic acid bacteria culture of mung bean obtained by culturing lactic acid bacteria in a culture medium containing the mung bean comprising steps of: removing a bacterial cell and an insoluble ingredient from the lactic acid bacteria culture of mung bean containing the mung bean extract and GABA, the culture being prepared according to the method of preparing the lactic acid bacteria culture of mung bean; and mixing a sub-material with the culture from which the bacterial cell and the insoluble ingredient are removed in the preceding step.
  • the invention provides a cosmetic composition containing a lactic acid bacteria culture of mung bean containing mung bean extract and GABA, as an effective ingredient.
  • the lactic acid bacteria culture of mung bean is prepared by the method of preparing the lactic acid bacteria culture of mung bean.
  • the lactic acid bacteria are lactic acid expressing glutamate dicarboxylase to convert MSG into GABA.
  • the cosmetic composition is prepared by the method of preparing the cosmetic composition containing the lactic acid bacteria culture of mung bean.
  • the cosmetic composition is a composition for promoting collagen biosynthesis.
  • the cosmetic composition is a composition for preventing or improving skin senescence.
  • the cosmetic composition is an anti-inflammatory composition.
  • the cosmetic composition is a composition for preventing or improving skin injury.
  • the lactic acid bacteria culture of mung bean containing the mung bean extract and GABA of the invention is able to exhibit the effect of preventing or improving the skin senescence through the collagen synthesis promotion. In addition, it can exhibit an anti-inflammatory effect and an effect of alleviating or improving the skin stimulus. Accordingly, the lactic acid bacteria culture of mung bean containing the mung bean extract and GABA can be usefully used as the cosmetic composition for promoting collagen biosynthesis, preventing or improving skin senescence, anti-inflammatory and preventing or improving skin injury.
  • FIG. 1 is a schematic view showing a method of preparing a lactic acid bacteria culture of mung bean using the mung bean, according to an embodiment of the invention
  • FIG. 2 shows a measurement result of a GABA content in a lactic acid bacteria culture of mung bean prepared in an embodiment 2, using a HPLC;
  • FIG. 3 shows a measurement result of a collagen synthesis promoting efficacy of a lactic acid bacteria culture of mung bean of the invention
  • FIG. 4 shows a measurement result of an inflammation alleviating efficacy by TPA (12-O-tetradecanonylphorbol-13-acetate) of a lactic acid bacteria culture of mung bean of the invention
  • FIG. 5 is a photograph showing an inflammation alleviating efficacy of a lactic acid bacteria culture of mung bean of the invention.
  • FIG. 6 shows a measurement result of an effect of a lactic acid bacteria culture of mung bean of the invention on secretion of interleukin-6 (IL-6) related to anti-inflammatory and hyperimmune reactions.
  • IL-6 interleukin-6
  • the inventors found out that when the lactic acid bacteria producing the GABA are seeded and cultured using mung bean extract as a raw material of a culture medium, it can be obtained a culture including effective ingredients of the mung bean, the GABA and various peptide ingredients produced by the lactic acid bacteria.
  • the culture can be used as the raw material of cosmetics for the senescence prevention and anti-inflammatory.
  • the inventors could obtain a natural material having merits of existing mung bean extract and lactic acid bacteria culture by successfully culturing Lactobacillus Sakei B2-16 (Deposit No. KFCC-11321) as the lactic acid bacteria, which is a lactic acid bacteria strain capable of producing GABA screened from Kimchi, (refer to Korean Patent Application No. 2003-5828), using culture medium ingredients of a raw material of mung bean.
  • a method of preparing a lactic acid bacteria culture of mung bean containing mung bean extract and GABA of the invention is as follows.
  • the lactic acid bacteria culture of mung bean obtained by culturing the lactic acid bacteria in a culture medium containing the mung bean can be obtained by a method comprising steps of (a) preparing mung bean extract; (b) preparing a culture medium including the mung bean extract obtained in the step (a) and monosodium glutamate (MSG); (c) seeding lactic acid bacteria in the culture medium prepared in the step (b), the bacteria being capable of converting the MSG into GABA ( ⁇ -Aminobutyric acid) by glutamate dicarboxylase; and (d) culturing the lactic acid bacteria seeded in the step (c) to prepare a lactic acid culture of mung bean containing the mung bean extract and the GABA.
  • a method comprising steps of (a) preparing mung bean extract; (b) preparing a culture medium including the mung bean extract obtained in the step (a) and monosodium glutamate (MSG); (c) seeding
  • step (a) it is advantageous to continuously supply the mung bean for obtaining the mung bean extract from a same area. Although there is a small difference between production yields depending on production areas, the production areas little affect final qualities of fermented products.
  • the mung bean is preferably washed before it is used as an ingredient of the culture medium, so as to remove agricultural chemicals remaining on a surface thereof.
  • cold water below 30° C. is preferably used and it is advantageous to carry out the process in a short time such as 30 minutes or less, so as to prevent water soluble nutrients from being lost.
  • the temperature of washing water is above 30° C. and the washing time exceeds 30 minutes, the nutrients of the mung bean can be lost.
  • peeled or non-peeled mung bean can be used as the mung bean used as the culture medium, which little affects the final product.
  • the washed mung bean is advantageously pulverized for an extracting process.
  • non-pulverized mung bean can be used for the extracting process of the invention.
  • the mung bean extract included in the culture medium can be obtained by using a variety of extraction solvents known in the art.
  • the usable extraction solvent can be at least one selected from a group consisting of water, absolute or water-containing low alcohol having a carbon number of 1 to 4 such as methanol, ethanol, butanol and propanol, mixing solvent of water and the low alcohol, acetone, ethyl acetate, chloroform, butyl acetate and 1,3-butylene glycol.
  • water is preferably used. That is, water is the best solvent, in consideration of stability of final product and culture of lactic acid bacteria. Further, it is possible to obtain the extract suitable for the invention using water.
  • An amount of the extract solvent used for obtaining the mung bean extract is 2 to 20 times as much as the mung bean, preferably 5 to 15 times.
  • an extract efficiency is lowered.
  • a concentration of effective ingredient after the extraction is low. Accordingly, when the effective ingredient is used as a fermentation source, a conversion rate of GABA is lowered.
  • an extraction temperature of the mung bean extract is preferably 40 ⁇ 70° C.
  • the extraction temperature is low, it takes much time to extract water soluble nutrients, and when the temperature is above 70° C., starch of the mung bean is gelatinized, so that it is difficult to separate the usable ingredients.
  • extraction time of the mung bean extract is preferably 3 to 24 hours, more preferably 6 to 18 hours. Even more preferably, the mung bean extract is extracted for 6 to 18 hours while being stirred at 30 to 100 rpm. When the extraction time is too short, a concentration of the nutrient is low and when the extraction time is too long, it can be a burden on the process.
  • the obtained mung bean extract is subject to a centrifugal separation to remove solid ingredients thereof, so that a supernatant solution is obtained, which is then added as nutrients of a culture medium for producing the GABA. At this time, the solid ingredients may be removed after the culturing.
  • the culture medium includes the mung bean extract and MSG.
  • the culture medium of the invention includes carbon source, nitrogen source, micro elements, surfactant or a mixture thereof, as well as the mung bean extract and MSG. More preferably, the culture medium includes the carbon and nitrogen sources. Even more preferably, the culture medium includes the carbon and nitrogen sources, and micro elements or surfactant.
  • the carbon source is at least one selected from a group consisting of glucose, sucrose, maltose, fructose, lactose, xylose, galactose, arabinose and a combination thereof, preferably a group consisting of sucrose, fructose, glucose, galactose, arabinose and lactose, more preferably a group consisting of sucrose, fructose and glucose.
  • An amount of the carbon source used is preferably 1 to 20 wt % for a total weight of the mung bean extract, more preferably 2 to 10 wt %, and even more preferably 3 to 6 wt %.
  • the nitrogen source is at least one selected from a group consisting of yeast extract, soytone, peptone, beef extract, trypton, casitone and a combination thereof, preferably a group consisting of yeast extract, peptone, trypton and soytone, more preferably yeast extract or soytone.
  • An amount of the nitrogen source used is preferably 1 to 20 wt % for a total weight of the mung bean extract, more preferably 1 to 10 wt % and even more preferably 2 to 4 wt %.
  • the micro element is at least one selected from a group consisting of magnesium sulfate, sodium sulfate, manganic sulfate, ferric sulfate, calcium chloride and a combination thereof.
  • An amount of the micro element used is preferably 0.001 to 1 wt % for a total weight of the mung bean extract, more preferably 0.01 to 1 wt % and even more preferably 0.03 to 0.3 wt %.
  • the surfactant used for the invention is at least one non-ionic surfactant selected from a group consisting of poly alcohol fatty acid such as monostealysineglycerine, polyethyleneglycol fatty acid such as stearic acid polyoxyl, polyoxyethylene alcohol such as raulmacrogol, sorbitan fatty acid such as oleic acid sorbitan, polyoxyethylene sorbitan fatty acid such as polysorbate and a combination thereof, more preferably polyoxyethylene sorbitan fatty acid and most preferably polysorbate.
  • poly alcohol fatty acid such as monostealysineglycerine
  • polyethyleneglycol fatty acid such as stearic acid polyoxyl
  • polyoxyethylene alcohol such as raulmacrogol
  • sorbitan fatty acid such as oleic acid sorbitan
  • polyoxyethylene sorbitan fatty acid such as polysorbate and a combination thereof, more preferably polyoxyethylene sorbitan fatty acid and most preferably poly
  • the culture medium is made by adding the non-ionic surfactant
  • the lactic acid bacteria can be normally cultured without the micro element. Accordingly, it is possible to eliminate the necessity of the micro element in the culture medium.
  • An amount of the surfactant used as the micro element is preferably 0.01 to 1 wt % for the total weight of the mung bean extract, more preferably 0.05 to 0.3 wt %.
  • an addition amount of the MSG is 1 to 30 wt % for the total weight of the mung bean extract, more preferably 1 to 20 wt %, and even more preferably 1 to 15 wt %.
  • the addition amount of the MSG is too much, the MSG which is not converted into the GABA remains on a final product.
  • the addition amount of the MSG is too little, the content of the GABA is too little in the final product.
  • the culture medium having all the ingredients (mung bean extract, MSG and other ingredients) mixed therein is preferably subject to a sterilizing treatment.
  • the sterilizing treatment is preferably carried out at 60 to 121° C. for 15 to 30 minutes, so as to minimize destruction of the nutrients.
  • the sterilizing treatment is carried out at a lower temperature or for a shorter time, the sterilization effect is reduced.
  • the sterilizing treatment is carried out at a higher temperature or for a longer time, the nutrients are destructed too much.
  • step (c) the lactic acid bacteria are seeded in the culture medium sterilized in the step (b).
  • glutamate decarboxylase which is expressed in the lactic acid bacteria participates in the conversion of the MSG into GABA.
  • the lactic acid bacteria used for the invention are not particularly limited as long as the bacteria express the glutamate decarboxylase, the bacteria are preferably Lactobacillus genus strain, most preferably Lactobacillus sakei or Lactobacillus brevis , more preferably at least one selected from a group consisting of Lactobacillus sakei B2-16 (Deposit No.
  • Lactobacillus brevis B1-14 Lactobacillus brevis B1-31, Lactobacillus brevis B2-22, Lactobacillus brevis B2-27, Lactobacillus brevis B2-29, Lactobacillus brevis B3-18, Lactobacillus brevis B3-25, Lactobacillus brevis B3-30 and Lactobacillus brevis A128, which are recorded as GABA producing strains in a Korean Patent Application No. 2003-5828.
  • the seeding amount of the lactic acid bacteria is such that the initial number of bacteria after the seeding is 10 5 to 10 8 cfu/ml. When the seeding amount is less than the range, the culturing time for producing the GABA is extended. To seed more bacteria is a burden on the production of spawn.
  • the culture medium containing the mung bean extract, to which the lactic acid bacteria are seeded in the step (c) is uniformly mixed to carry out the fermentation at 20 to 35° C.
  • the temperature is below the range, the fermentation is not easily carried out.
  • the temperature is above the range, the lactic acid bacteria poor in the heat die out, so that the GABA cannot be produced.
  • the culturing time of the lactic acid bacteria is preferably 30 to 90 hours, and more preferably 48 to 72 hours.
  • a method of preparing a cosmetic composition containing a lactic acid culture of mung bean containing mung bean extract and GABA, as an effective ingredient is as follows.
  • the cosmetic composition containing the lactic acid culture of mung bean as an effective ingredient can be prepared according to a method comprising steps of: removing a bacterial cell and an insoluble ingredient from the lactic acid bacteria culture of mung bean containing the mung bean extract and GABA, the culture being prepared according to the method of preparing the lactic acid bacteria culture of mung bean; and mixing a sub-material with the culture from which the bacterial cell and the insoluble ingredient are removed in the preceding step.
  • the bacterial cell and insoluble ingredient are removed through a treatment of activated carbon or typical filtering method (for example, filter press, membrane process and the like).
  • a typical filtering method is used after the treatment of activated carbon.
  • the bacterial cell and insoluble ingredient are subject to a decoloring process with the treatment of activated carbon.
  • the culture is passed to a column having activated carbon packed therein or is directly mixed with the activated carbon.
  • the invention is not particularly limited with regard to this.
  • powders of activated carbon may be directly added to the culture after the culturing, so as to simplifying the processes.
  • the activated carbon is classified into powder and particulate types depending on shapes thereof.
  • the powder-type activated carbon is typically used with added to the liquid, for the discoloring.
  • the addition amount of the activated carbon is preferably 0.1 to 10 wt % of the culture, more preferably 0.5 to 5 wt %, and even more preferably 1.0 to 3.0 wt %. When the activated carbon is too much, it much costs to remove the activated carbon. When the activated carbon is too little, the discoloring is insufficient.
  • a heating process is immediately carried out which interrupts the fermentation of microbes and promotes the reaction of the activated carbon.
  • the final temperature of the heating is preferably 40 to 100° C. When the final temperature is below 40° C., the microbes used for the fermentation are not extinct, so that the reaction time is prolonged. In addition, when the final temperature is above 100° C., a reverse reaction may occur.
  • the culture heated is left alone for 3 to 24 hours while being stirred so that the activated carbon is not settled. When it is under 3 hours, the sufficient discoloring is not achieved. When it is above 24 hours, it becomes a burden on the process. After that, the bacterial cell and insoluble ingredient are removed with the typical filtering method (for example, filter press, membrane filter, etc.).
  • the typical filtering method for example, filter press, membrane filter, etc.
  • a cosmetic composition packed into respective formulations is prepared.
  • the lactic acid bacteria culture of mung bean containing the mung bean extract and GABA which is obtained by the method of the invention, has higher effects of promoting the collagen synthesis and alleviating the skin inflammation, as compared to a prior mung bean product used for the cosmetics, and can be used for the cosmetics applied to the senescence prevention and anti-inflammation.
  • the lactic acid bacteria culture of mung bean containing the mung bean extract and GABA which is developed by the invention, has many advantages.
  • the inventors conducted a Sircol Assay method. As a result, it was confirmed that when the 0.01% lactic acid bacteria culture of mung bean containing the mung bean extract and GABA was treated, the collagen secretion was promoted in a same degree as the collagen secretion induced when 10 ⁇ M genistein (Sigma, USA) was treated which was used as a positive control group. This shows that the collagen secretion was promoted by 30% or more, as compared to a non-treatment group.
  • the inventors induced inflammation in a test animal and then treated it with the culture. As a result, it was confirmed that when the 0.5% lactic acid bacteria culture of mung bean containing the mung bean extract and GABA, the inflammation was alleviated.
  • the invention provides a cosmetic composition containing the lactic acid bacteria culture of mung bean containing the mung bean extract and GABA, as an effective ingredient.
  • the cosmetic composition of the invention may contain other ingredients providing a synergetic effect to the main effects, in a range not deteriorating the main effects of the invention.
  • the cosmetic composition may take a form of solution, emulsion, viscous mixture and the like.
  • the cosmetic composition of the invention is not particularly limited with regard to its formulations, it may be formulated into skin adhesion type cosmetics, such as latex, toilet water, cream, lotion, essence, pack and gel, cosmetics having formulations such as powder, lipstick, make-up base and foundation, and washing cosmetics such as shampoo, rinse, body cleanser, cosmetic solution, cleansing foam, cleansing cream, cleansing water and soap, for example.
  • skin adhesion type cosmetics such as latex, toilet water, cream, lotion, essence, pack and gel
  • cosmetics having formulations such as powder, lipstick, make-up base and foundation
  • washing cosmetics such as shampoo, rinse, body cleanser, cosmetic solution, cleansing foam, cleansing cream, cleansing water and soap, for example.
  • the other ingredients may be appropriately selected and mixed by a skilled in the art, depending on formulations or use purposes of the cosmetics.
  • the cosmetic composition of the invention may comprise a composition selected from a group consisting of water soluble vitamin, oil soluble vitamin, high molecular peptide, high molecular polysaccharide, sphingo lipid and extract of seaweeds.
  • the cosmetic composition of the invention may be mixed with other ingredients which are typically mixed in the cosmetics depending on the necessities, in addition to the essential ingredients.
  • oil and fat ingredient may be added.
  • moisturizer may be added to moisturizer, emollient agent, surfactant, organic and inorganic cosmetics, organic powders, ultraviolet absorbent, antiseptic, sterilizer, antioxidant, plant extract, pH conditioner, alcohol, pigment, perfume, blood stream promoter, cold sense agent, anhydrotics, purified water and the like.
  • the other ingredients may be added in a range not deteriorating the objects and effects of the invention, preferably in an amount of 0.01 ⁇ 0.5 wt %, more preferably 0.01 ⁇ 3 wt %.
  • the mung bean was washed with cold water of 30° C. or less and pulverized. Then, 100 g of mung bean was added with water, which is extraction solvent, and then extracted at 60° C. for 12 hours. After that, the supernatant solution was removed through a centrifugal separation (6000 rpm, 15 minutes), so that 800 g of mung bean extract was obtained.
  • the 500 g of mung bean extract which was obtained in the embodiment 1, was mixed with 500 g of culture medium having ingredients and contents shown in a Table 1.
  • the mixture was heated for sterilization at 80° C. for 30 minutes to prepare a culture medium for culturing lactic acid bacteria and including the mung bean.
  • Lactobacillus sakei B2-16 (Deposit No. KFCC-11321) (refer to a Korean Patent Application No. 2003-5828) as the lactic acid bacteria was seeded in the culture so that the initial number of bacteria was 10 7 to 10 8 cfu/ml.
  • the culture was cultured at 30° C. for 60 hours while being stirred at 50 rpm.
  • a lactic acid bacteria culture of mung bean containing mung bean extract and GABA was obtained.
  • the culture as a sample was analyzed with a reversed-phase HPLC (Waters) with regard to the GABA content thereof.
  • the analysis conditions using the reversed-phase HPLC was established with reference to reports of Ibolya et al.
  • the sample was subject to the centrifugal separation at 8000 rpm for 10 minutes and the supernatant solution was filtered with a membrane filter and then diluted in the distilled and deionized water in a proper concentration.
  • the prepared sample was subject to the reversed-phase HPLC after derivatization of a free-column reaction using o-phthaldialdehyde (OPA).
  • OPA solution pH 9.3 was prepared by mixing 5.0 ml of methanolic OPA, 20 ml of borate buffer solution (pH 9.9) and 50 ⁇ l of 2-mercaptoethanol.
  • the methanolic OPA was prepared by dissolving 2.56 g of OPA in 50 ml of methanol and the borate buffer solution was prepared by mixing 0.2M boric acid and 0.2M sodium hydroxide in a ratio of 50:50 (v/v) and then adding 0.2M potassium chloride thereto.
  • the OPA solution was used after 2 hours and was stable for 1 week after the preparation.
  • the prepared OPA solution 380 ⁇ l and the sample 120 ⁇ l were mixed well and then reacted at the room temperature for 8 minutes. At this time, if it is left alone at the room temperature for a long time, peak shape or area of the reversed-phase HPLC may be different due to instability of the derivative. Accordingly, the reversed-phase HPLC was carried out without leaving it alone for 1-2 hours or more at the room temperature. Then, the derivatized sample 20 ⁇ l was introduced in the column.
  • HPLC column a XTerra column (Waters: RP 18 5 m, 4.6 mm ⁇ 150 mm) was used.
  • mobile phases 0.05M sodium acetate (pH 7.2) was used as a solvent A, and a mixture (pH 7.2) in which 0.1M sodium acetate, acetonitrile (HPLC grade) and methanol (HPLC grade) were mixed in a ratio of 46:44:10 (v/v/v) was used as a solvent B.
  • Concentration gradients of the mobile phases were as follows: starting the analysis with the solvent A being 100%, the solvent B was made to be 100% after 30 minutes, the solvent B was made to be 100% until after 40 minutes, the solvent A was made to be 100% again until after 45 minutes and the solvent A was made to be 100% until after 60 minutes.
  • the flow rate of the mobile phase was fixed to be 1 ml/min. and the GABA was detected with a U.V. detector. Under these conditions, the holding time of GABA and glutamate were 21.01 and 9.89 minutes, respectively and a limit concentration of the detection was 0.1 mM. In addition, if the concentration of the GABA exceeds 10 mM, since it exceeds the upper limit of the detector, it was diluted to correspond to it and then measured. At this time, 99% GABA from Sigma which was commercialized for reagent was used as a standard material.
  • the Sircol Assay method was used. All collagen has a structure of [Gly-X-Y]n. According to the sircol assay method, it is used the dye reagent which is peculiarly coupled to such portion to measure the collagen in a manner of quantifying the coupled structure of collagen and dye reagent.
  • the cell lines used to measure the collagen was fibroblast NIH 3T3 cell lines (ATCC, USA) and maintained while being cultured in a DMEM culture medium (FBS 10%).
  • FBS 10% fetal calf serum
  • 4 ⁇ 10 4 cells were divided in each of 24-well plates. Each of the well plates was filled with 1 ml of cell culture. At this time, before treating the first material, 500 ⁇ l of cell culture was divided therein and cultured for 12 hours, for adhesion of the cells.
  • genistein (Sigma, USA), which was known to have an excellent collagen synthesis effect, was dissolved in DMSO.
  • the treatment concentrations of the lactic acid bacteria culture of mung bean in the embodiment 2 and the genistein were 0.005%, 0.01% and 0.10% and 0.5 ⁇ M, 1 ⁇ M and 10 ⁇ M, respectively.
  • the lactic acid bacteria culture of mung bean in the embodiment 2 and the genistein were divided in the 24-well plates that were cultured for 12 hours, by 500 ⁇ l, respectively, and then cultured for 24 hours. After the culturing, 800 ⁇ l of supernatant solution was obtained and subject to the centrifugal separation at 12000 g, so that it was obtained the culture except the cells.
  • the culture was centrifugally separated and then supernatant solution was obtained which was then used as a measurement sample.
  • the water soluble collagen provided to obtain a quantitative standard curve was divided in standard solution with regard to concentrations thereof, and the culture to be tested was divided in 1.5 ml tubes by 500 ⁇ l, with 4 groups.
  • the supernatant solution was mixed with Sirius red dye 1 ml which was provided from Sircol assay (Biocolor, N. Ireland) and then left alone at the room temperature for 30 minutes.
  • the mixture was subject to the centrifugal separation for 5 minutes as 16,000 g, washed with ethanol two times and then again dissolved in 1 ml of 5N NaOH. This was moved into 96-well plates in a proper amount and then absorbency thereof was measured at 540 nm for quantification with a visible/ultraviolet absorption measuring device.
  • CD-1 mouse male & female, 6-8 weeks, Charles River, USA
  • 10 ⁇ l of TPA (12-O-tetradecanonylphorbol-13-acetate) 0.03% (wt/vol. in acetone) solution was applied to inside and outside of both ears of the test animals. Due to the treatment material, the ear was thickened and there occurred an inflammatory reaction.
  • TPA (12-O-tetradecanonylphorbol-13-acetate
  • clofibrate (1 mM) and Wy14643 (1 mM) which are agonists of PPAR CL (Sheu et al., The Journal of Investigative Dermatology, 118, pp 94-101, 2002), and as a test material, the lactic acid bacteria culture of mung bean in the embodiment 2 were applied to the both surfaces of the ears in an amount of 30 ml/cm 2 , respectively, at 45 minutes and 4 hours after the inflammation induction.
  • CytElisa Human IL-6 ELISA kit (USA) was used. The test was conducted as follows, according to a method provided from the maker. 100 ⁇ l of culture solution after the culturing for 24 hours was extracted and divided in 96-well plates. Then, 25 ⁇ l of anti-interleukin-6 was put in the plates which were then sealed with a plate sealer. Then, it was reacted at the room temperature for 3 hours and then washed with PBS five times. Then, goat anti-rabbit alkaline phosphatase was pun in each plate which was again sealed. Then, it was reacted at the room temperature for 45 minutes.
  • a color generating reagent was divided therein in an amount of 200 ⁇ l, respectively. Then, it was reacted at the room temperature until there occurred a color change. When there occurred the color change, a reaction terminating solution was divided in an amount of 50 ⁇ l, respectively. Then, the absorbency was measured at 490 nm to measure the content of IL-6. A result thereof is shown in FIG. 6 .
  • ( ⁇ ) is a group in which only vehicle was treated after the ultraviolet illumination, normal is a state before the ultraviolet illumination and the others are groups to which the materials were treated after the ultraviolet illumination, as described above.
  • lactic acid bacteria culture of mung bean of the embodiment 3 1.00 (wt %) oil and fat proper amount sodium hydroxide proper amount sodium chloride proper amount perfume small amount
  • soap was prepared according to the mixing ratio.
  • lactic acid bacteria culture of mung bean of the embodiment 3 3.00 (wt %) L-ascorbic acid-2-magnesium phosphate 1.00 water soluble collagen (1% aqueous solution) 1.00 sodium citric acid 0.10 citric acid 0.05 extract of licorice 0.20 1,3-butyleneglycol 3.00
  • lotion Based on purified water of 100, lotion was prepared according to the mixing ratio.
  • lactic acid bacteria culture of mung bean of the embodiment 3 1.00 (wt %) polyethyleneglycolmonostearate 2.00 self-emulsified type mono stearic acid glycerine 5.00 cetyl alcohol 4.00 squalene 6.00 tri2-ethyl hexanoic acid glycerine 6.00 glycosphingolipid 1.00 1,3-butyleneglycol 7.00
  • cream Based on purified water of 100, cream was prepared according to the mixing ratio.
  • lactic acid bacteria culture of mung bean of the embodiment 3 5.00 (wt %) polyvinyl alcohol 13.00 L-ascorbic acid-2-magnesium phosphate 1.00 lauroylhydroxyproline 1.00 water soluble collagen (1% aqueous solution) 2.00 1,3-butyleneglycol 3.00 ethanol 5.00
  • pack was prepared according to the mixing ratio.
  • lactic acid bacteria culture of mung bean of the embodiment 3 2.00 (wt %) hydroxyethylenecellulose (2% aqueous solution) 12.00 xanthan gum (2% aqueous solution) 2.00 1,3-butyleneglycol 6.00 dark glycerine 4.00 sodium hyaluronate (1% aqueous solution) 5.00
  • toilet water Based on purified water of 100, toilet water was prepared according to the mixing ratio.
  • the lactic acid bacteria culture of mung bean containing the mung bean extract and GABA of the invention is able to exhibit the effect of preventing or improving the skin senescence through the collagen synthesis promotion. In addition, it can exhibit an anti-inflammatory effect and an effect of alleviating or improving the skin stimulus. Accordingly, the lactic acid bacteria culture of mung bean containing the mung bean extract and GABA can be usefully used as the cosmetic composition for promoting collagen biosynthesis, preventing or improving skin senescence, anti-inflammatory and preventing or improving skin injury, as the cosmetic composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US11/994,866 2005-07-07 2006-07-07 Lactic acid bacteria culture of mung bean and the preparation method of the same, and the cosmetic composition comprising the same Abandoned US20090068150A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2005-0061136 2005-07-07
KR1020050061136A KR101221239B1 (ko) 2005-07-07 2005-07-07 녹두 유산균 배양물 및 이의 제조방법, 그리고 이를함유하는 화장료 조성물
PCT/KR2006/002663 WO2007007989A1 (en) 2005-07-07 2006-07-07 Lactic acid bacteria culture of mung bean and the preparation method of the same, and the cosmetic composition comprising the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2006/002663 A-371-Of-International WO2007007989A1 (en) 2005-07-07 2006-07-07 Lactic acid bacteria culture of mung bean and the preparation method of the same, and the cosmetic composition comprising the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/525,661 Continuation US20150044313A1 (en) 2005-07-07 2014-10-28 Lactic acid bacteria culture of mung bean and the preparation method of the same, and the cosmetic composition comprising the same

Publications (1)

Publication Number Publication Date
US20090068150A1 true US20090068150A1 (en) 2009-03-12

Family

ID=37637324

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/994,866 Abandoned US20090068150A1 (en) 2005-07-07 2006-07-07 Lactic acid bacteria culture of mung bean and the preparation method of the same, and the cosmetic composition comprising the same
US14/525,661 Abandoned US20150044313A1 (en) 2005-07-07 2014-10-28 Lactic acid bacteria culture of mung bean and the preparation method of the same, and the cosmetic composition comprising the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/525,661 Abandoned US20150044313A1 (en) 2005-07-07 2014-10-28 Lactic acid bacteria culture of mung bean and the preparation method of the same, and the cosmetic composition comprising the same

Country Status (4)

Country Link
US (2) US20090068150A1 (ko)
JP (1) JP2009501160A (ko)
KR (1) KR101221239B1 (ko)
WO (1) WO2007007989A1 (ko)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110038969A1 (en) * 2009-08-11 2011-02-17 Asia Optical Co., Inc. Fermented composition of mung bean hulls, method for forming thereof, and anti-oxidation and anti-inflammation composition using the same
CN110484526A (zh) * 2019-09-17 2019-11-22 黑龙江八一农垦大学 一种绿豆中谷氨酸脱羧酶的提取纯化方法
CN110522684A (zh) * 2019-07-22 2019-12-03 北京京瑜科技有限公司 一种蛹虫草-绿豆双向液体发酵工艺
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
CN114304514A (zh) * 2021-12-08 2022-04-12 北京工商大学 富含gaba与akg的绿豆乳及其制备方法
CN115006310A (zh) * 2022-07-05 2022-09-06 菏泽市亿鑫生物科技有限公司 绿豆萌芽发酵物，含其皮肤外用剂及其制备方法和应用
CN115040449A (zh) * 2022-07-08 2022-09-13 广州悦荟化妆品有限公司 一种具有抗炎、舒缓、修护功效的绿豆发酵液、混合发酵液及其制备方法与应用
CN115089529A (zh) * 2022-08-03 2022-09-23 肽源（广州）生物科技有限公司 一种具有祛痘功效的绿豆皮发酵产物及其制备方法和应用
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
CN115836997A (zh) * 2022-11-02 2023-03-24 菏泽市亿鑫生物科技有限公司 一种绿豆籽发酵物，含其皮肤外用剂及其制备方法和应用
CN117679354A (zh) * 2024-02-04 2024-03-12 知想(山东)医疗科技有限公司 含有γ-氨基丁酸的外泌体制剂及其制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101423573B1 (ko) * 2007-07-02 2014-07-30 주식회사 엘지생활건강 항산화 활성을 갖는 화장료 조성물
KR100886109B1 (ko) * 2007-12-27 2009-02-27 장흥군 생약재 발효추출물을 함유한 기능성 비누의 조성물
KR101040508B1 (ko) * 2008-07-31 2011-06-16 주식회사 코리아나화장품 녹두 발효-효소 추출액을 포함하는 피부 노화 방지 및 보습용 화장료 조성물
WO2010013852A1 (en) 2008-07-31 2010-02-04 Coreana Cosmetics, Co., Ltd Cosmetic composition for anti-aging of the skin comprising phaseolus radiatus seed extracts by fermentation and enzyme treatment
JP5791009B2 (ja) * 2008-12-22 2015-10-07 アサヒグループホールディングス株式会社 乳酸菌およびそれらを用いた飲食物又は化粧品
BR112014000414B1 (pt) * 2011-07-13 2021-06-22 Foodchek Systems, Inc Meio de cultura para crescimento seletivo de listeria spp e métodos para cultura seletiva de listeria e para detecção de listeria
DE102011110996A1 (de) * 2011-08-18 2013-02-21 Evonik Goldschmidt Gmbh Verfahren zur Herstellung von 4-Aminobuttersäure aus Algen
KR101501328B1 (ko) * 2011-12-28 2015-03-18 동의대학교 산학협력단 피부개선용 조성물
CN103897998B (zh) * 2012-12-25 2016-06-29 北京中天神舟航天食品技术研究院 唾液乳杆菌及其应用以及功能食品组合物及其制备方法
WO2017063909A1 (en) * 2015-10-13 2017-04-20 Unilever N.V. A process for preparing metabolites by reaction of a prebiotic component with a probiotic component
KR102325947B1 (ko) * 2020-02-05 2021-11-15 주식회사 에이치이엠파마 신규한 락토바실러스 사케이 hem224 균주, 및 상기 균주 또는 이의 배양물을 포함하는 염증 또는 천식의 치료용 조성물
KR102664144B1 (ko) * 2021-08-05 2024-05-10 주식회사 엘씨에스바이오텍 신규한 곡류 발효물, 그 곡류 발효물의 피부 보호 용도, 피부 유용 물질 스크리닝 방법 및 산화적 스트레스로 인한 피부 손상 예측 방법
IT202200013882A1 (it) * 2022-07-04 2024-01-04 Alfasigma Spa Prodotto di fermentazione per il trattamento di malattie infiammatorie.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653967A (en) * 1992-10-23 1997-08-05 R.I.T.A. Corporation Cosmetic product including water soluble fiber
US20020106424A1 (en) * 2001-02-05 2002-08-08 Kikkoman Corporation Y-aminobutyric acid-containing natural food material and method for manufacturing the same
US20030113403A1 (en) * 2000-04-07 2003-06-19 Daniel Jaeger Cultured protein hydrolysate
US20080003309A1 (en) * 2004-03-11 2008-01-03 Hye Won Lee Yoghurt Formulation Cosmetic Composition

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5826726B2 (ja) * 1975-06-13 1983-06-04 カネボウ株式会社 ケシヨウリヨウ
JPH0517363A (ja) * 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
JP2704493B2 (ja) * 1994-02-18 1998-01-26 京都府 発酵食品の製造方法
JP3963972B2 (ja) * 1995-11-17 2007-08-22 三省製薬株式会社 皮膚外用剤
US5958976A (en) * 1997-09-19 1999-09-28 E-L Management Corp. Composition and method for reducing stinging in skin
FR2779058B1 (fr) * 1998-05-29 2003-02-21 Dior Christian Parfums Utilisation d'au moins une saponine ou un sapogenol cosmetiquement acceptable, comme agent cosmetique destine a augmenter la quantite de collagene iv dans la jonction dermo-epidermique
JP4332247B2 (ja) * 1999-01-21 2009-09-16 大洋香料株式会社 γ−アミノ酪酸高生産能を有する乳酸菌、及びその乳酸菌を使用したγ−アミノ酪酸高含有発酵食品とその製造法。
JP2001107286A (ja) * 1999-09-30 2001-04-17 Nkk Corp 溶接缶用錫めっき鋼板及びその製造方法
JP2001252047A (ja) * 2000-03-13 2001-09-18 Biox:Kk 発酵食品
JP2002015499A (ja) * 2000-06-30 2002-01-18 Ricoh Co Ltd 光ディスクドライブ、光ディスク作成システム及び情報記憶媒体
JP4612180B2 (ja) * 2000-12-19 2011-01-12 株式会社ヤクルト本社 皮膚外用剤
JP2002265343A (ja) * 2001-03-07 2002-09-18 Ichimaru Pharcos Co Ltd 化粧料組成物
KR20030089710A (ko) * 2001-04-06 2003-11-22 가부시키가이샤 도요학코 미용화장품 소재 및 그 제조방법
JP2003137768A (ja) * 2001-08-21 2003-05-14 Shiseido Co Ltd 抗老化剤
JP2003113066A (ja) * 2001-10-01 2003-04-18 Ai Corporation:Kk 化粧料
JP4344143B2 (ja) 2003-01-10 2009-10-14 キリンホールディングス株式会社 風味の良いｇａｂａ高含有乳酸菌発酵飲食品及び調味食品の製造法
KR100549094B1 (ko) * 2003-01-29 2006-02-06 변유량 신규한 락토바실러스 속 균주 및 이를 이용한 감마-아미노부티르산의 제조방법
JP4596304B2 (ja) * 2003-03-04 2010-12-08 株式会社ファーマフーズ 成長ホルモン分泌促進組成物
JP4073358B2 (ja) * 2003-04-28 2008-04-09 株式会社武蔵野免疫研究所 化粧品
KR100547018B1 (ko) * 2003-05-02 2006-01-31 주식회사 바름인 유산균에 의해 감마-아미노부틸산이 강화된 발효물의생산방법과 이를 이용하여 생산된 감마-아미노부틸산이강화된 발효물 및 그의 이용
JP4027858B2 (ja) * 2003-07-02 2007-12-26 独立行政法人科学技術振興機構 超短光パルス信号の分散補償方法およびその装置
KR100628649B1 (ko) * 2003-12-22 2006-09-26 주식회사 코리아나화장품 피부자극 완화 효과의 녹두 추출물 개발 및 이를 응용한화장료 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653967A (en) * 1992-10-23 1997-08-05 R.I.T.A. Corporation Cosmetic product including water soluble fiber
US20030113403A1 (en) * 2000-04-07 2003-06-19 Daniel Jaeger Cultured protein hydrolysate
US20020106424A1 (en) * 2001-02-05 2002-08-08 Kikkoman Corporation Y-aminobutyric acid-containing natural food material and method for manufacturing the same
US20080003309A1 (en) * 2004-03-11 2008-01-03 Hye Won Lee Yoghurt Formulation Cosmetic Composition

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784912B2 (en) 2009-08-11 2014-07-22 Food Industry Research & Development Institute Fermented composition of mung bean hulls, method for forming thereof, and anti-oxidation and anti-inflammation composition using the same
US20110038969A1 (en) * 2009-08-11 2011-02-17 Asia Optical Co., Inc. Fermented composition of mung bean hulls, method for forming thereof, and anti-oxidation and anti-inflammation composition using the same
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11998575B2 (en) 2016-03-31 2024-06-04 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11633451B2 (en) 2016-03-31 2023-04-25 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
CN110522684A (zh) * 2019-07-22 2019-12-03 北京京瑜科技有限公司 一种蛹虫草-绿豆双向液体发酵工艺
CN110484526A (zh) * 2019-09-17 2019-11-22 黑龙江八一农垦大学 一种绿豆中谷氨酸脱羧酶的提取纯化方法
CN114304514A (zh) * 2021-12-08 2022-04-12 北京工商大学 富含gaba与akg的绿豆乳及其制备方法
CN115006310A (zh) * 2022-07-05 2022-09-06 菏泽市亿鑫生物科技有限公司 绿豆萌芽发酵物，含其皮肤外用剂及其制备方法和应用
CN115040449A (zh) * 2022-07-08 2022-09-13 广州悦荟化妆品有限公司 一种具有抗炎、舒缓、修护功效的绿豆发酵液、混合发酵液及其制备方法与应用
CN115089529A (zh) * 2022-08-03 2022-09-23 肽源（广州）生物科技有限公司 一种具有祛痘功效的绿豆皮发酵产物及其制备方法和应用
CN115836997A (zh) * 2022-11-02 2023-03-24 菏泽市亿鑫生物科技有限公司 一种绿豆籽发酵物，含其皮肤外用剂及其制备方法和应用
CN117679354A (zh) * 2024-02-04 2024-03-12 知想(山东)医疗科技有限公司 含有γ-氨基丁酸的外泌体制剂及其制备方法

Also Published As

Publication number Publication date
WO2007007989A1 (en) 2007-01-18
KR101221239B1 (ko) 2013-01-11
JP2009501160A (ja) 2009-01-15
KR20070006960A (ko) 2007-01-12
US20150044313A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
US20150044313A1 (en) Lactic acid bacteria culture of mung bean and the preparation method of the same, and the cosmetic composition comprising the same
JP5972667B2 (ja) ヒアルロン酸合成促進剤及び皮膚外用剤
KR101147541B1 (ko) 우방자 발효물을 함유하는 피부외용제 조성물
JP2016074647A (ja) 保湿効果を有する乳酸菌米発酵物
JP2023171950A (ja) 抗老化剤、抗酸化剤、抗炎症剤、及び美白剤、並びに、化粧料
KR20130114502A (ko) 산수유 추출물을 유효성분으로 함유하는 화장료 조성물
JP3619185B2 (ja) 化粧料
JP2006311804A (ja) グルコン酸亜鉛を配合する美白組成物
CN115737478B (zh) 沙漠藻护肤原料在制备皮肤舒缓剂中的应用
KR101814389B1 (ko) 번행초 추출물을 함유한 화장료 조성물
JP3806419B2 (ja) 化粧料
FR3034667A1 (fr) Composition cosmetique et/ou dermatologique contre l'acne
JP2010229062A (ja) 美白剤
KR101008954B1 (ko) 앗싸이 베리의 발효물을 포함하는 화장료 조성물,약학조성물 및 앗싸이 베리의 발효방법
JP2019178123A (ja) カンゾウ抽出発酵物、美白剤、抗老化剤、皮膚化粧料及び飲食品
KR102154139B1 (ko) 고로쇠나무 수액의 발효액, 카카오닙스 추출물 및 석류피 추출물을 포함하는 조성물
KR101951646B1 (ko) 스피룰리나 마리노박터 발효 추출물을 유효성분으로 포함하는 항산화 및 주름개선용 화장료 조성물
JP6521211B2 (ja) セロビオースリピッドを有効成分とする賦活化剤
KR101719723B1 (ko) 황금연꽃바나나 추출물을 유효성분으로 함유하는 화장료 조성물
CH694904A5 (fr) Utilisation d'un extrait de Rhodiola crenulata, par voie topique.
WO2006106993A1 (ja) メラニン生成抑制剤
KR20240114093A (ko) 조록싸리 꽃 유래 앱솔루트 타입 정유를 유효성분으로 포함하는 피부재생 또는 피부장벽 강화용 조성물
EP3134100B1 (fr) Compositions cosmetiques a application topique comprenant des cellules vegetales de bougainvillier
FR3034989A1 (fr) Compositions cosmetiques comprenant des oligomeres d'acide hyaluronique et des cellules vegetales dedifferenciees et elicitees de bougainvillier encapsulant un extrait de safran
KR101656322B1 (ko) 가르데노시드를 포함하는 피부 주름 개선 또는 피부 탄력 증진용 조성물

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOVAN CO., LTD., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARK, CHANG-SEO;NAM, SANG-JUNE;CHOI, WANG-KEUN;AND OTHERS;REEL/FRAME:021551/0671

Effective date: 20080110

Owner name: DOOSAN CORPORATION, KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARK, CHANG-SEO;NAM, SANG-JUNE;CHOI, WANG-KEUN;AND OTHERS;REEL/FRAME:021551/0671

Effective date: 20080110

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION